3-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)propanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)propanamide
• 英文别名: 3-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]propanamide
• 化学式: C₉H₂₀N₂O₄
• 分子量: 220.27
• InChiKey: DCFFWBXDVFMJMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  15
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  96.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE DÉGRADATION/PERTURBATION DE LA PROTÉINE ARGININE MÉTHYLTRANSFÉRASE 5 (PRMT5) ET MÉTHODES D'UTILISATION
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2019165189A1

  公开（公告）日：2019-08-29

  Disclosed are protein arginine methyltransferase 5 (PRMT5) degradation / disruption compounds including a PRMT5 ligand, a degradation / disruption tag and a linker, and methods for use of such compounds in the treatment of PRMT5-mediated diseases. The PRMT5 degraders disclosed herein offer a novel mechanism for treating PRMT5-mediated diseases compared to small molecule inhibitors of PRMT5 activity.

  本文披露了包括PRMT5配体、降解/破坏标签和连接剂在内的蛋白质精氨酸甲基转移酶5（PRMT5）降解/破坏化合物，以及利用这些化合物治疗PRMT5介导疾病的方法。本文披露的PRMT5降解剂提供了一种与PRMT5活性的小分子抑制剂相比治疗PRMT5介导疾病的新机制。
• CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE
  申请人：ALHAMADSHEH MAMOUN M.

  公开号：US20160045609A1

  公开（公告）日：2016-02-18

  A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

  提供了一种活性成分的传递系统以及制备和使用该系统的方法。传递系统具有（i）一种选择性为受试者血清中内源性血浆蛋白的配体；和（ii）一个连接物，配置为共价地将配体操作性地附加到活性成分上，以增加活性成分在血清中的半衰期。
• [EN] COMPOUNDS AND METHODS OF TREATING DISEASES<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE MALADIES
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2022068933A1

  公开（公告）日：2022-04-07

  Provided are heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof, and methods for identifying such heterobifunctional compounds.

  提供了异双功能化合物（例如，双功能小分子化合物），包含一种或多种异双功能化合物的组合物，使用异双功能化合物治疗患有某些疾病的需要的受试者的方法，以及鉴定此类异双功能化合物的方法。
• Targeted conformationally-constrained kinked endosomal disrupting peptides
  申请人：The University of Kansas

  公开号：US10766928B2

  公开（公告）日：2020-09-08

  A peptide can have a sequence of one of SEQ ID NOs: 78-91. A conformationally-constrained kinked peptide includes: a conformationally-constraining portion and a kinked portion linked to the conformationally-constraining portion that conformationally constrains the kinked portion having a peptide sequence of one of SEQ NOs: 78-97. A cell-targeting compound can include a conformationally-constrained kinked peptide having a peptide sequence of one of SEQ ID NOs: 78-97. The peptide sequence can be one of SEQ ID NOs: 78-97, or 78-91, or 92-97. A cell-targeting compound can include a conformationally-constrained kinked peptide linked to a branched linker with one branch arm linked to a specific targeting moiety and one branch arm linked to a general targeting moiety. The specific targeting moiety can be an antibody. The general targeting moiety can be a lipid or cholesterol derivative.

  多肽可以具有 SEQ ID NOs: 78-91 中的一个序列。构象约束扭结肽包括：构象约束部分和与构象约束部分相连的扭结部分，构象约束扭结部分具有 SEQ ID NOs: 78-97 之一的肽序列。细胞靶向化合物可包括具有 SEQ ID NOs: 78-97 之一肽序列的构象受限扭结肽。肽序列可以是 SEQ ID NOs：78-97、78-91 或 92-97 中的一种。细胞靶向化合物可包括与支链连接的构象受限扭结肽，其一个支臂与特异性靶向分子连接，一个支臂与一般靶向分子连接。特异性靶向分子可以是抗体。一般靶向分子可以是脂质或胆固醇衍生物。
• ENZYMATIC CONJUGATION OF POLYPEPTIDES
  申请人：Innate Pharma

  公开号：EP2793947B1

  公开（公告）日：2021-02-03